(ZGNX) |
| 0 (0%) 09-02 23:39 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 15.95 |
| Resistance 1: | 14.65 |
| Pivot price: | 13.57 |
| Support 1: | 12.54 |
| Support 2: | 10.43 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.440 |
| Book Value | 4.370 |
| PEG Ratio | 0.00 |
| Gross Profit | 4.808 |
| Profit Margin (%) | 5.14 |
| Operating Margin (%) | 9.53 |
| Return on Assets (ttm) | 3.6 |
| Return on Equity (ttm) | 10.5 |
Company news
Thu, 27 Aug 2026
Zogenix Inc (ZGNX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Wed, 19 Jan 2022
Zogenix Stock Rockets on News of Acquisition by UCB - Barron's
Wed, 19 Jan 2022
Latham & Watkins Advises Zogenix in US$1.9 Billion Acquisition by UCB - lw.com
Wed, 03 Feb 2021
Big $7.2 billion cannabinoid drug acquisition puts Bay Area drug makers in competition - The Business Journals
Thu, 03 Dec 2020
Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies - PR Newswire
Thu, 25 Jun 2020
Zogenix wins approval for new drug to treat rare type of childhood epilepsy - STAT
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
